Halozyme Therapeutics (HALO) SEC Filings & 10K Form

$44.71
-0.68 (-1.50%)
(As of 05/17/2024 ET)

Recent Halozyme Therapeutics SEC Filings

DateFilerForm TypeView
05/07/2024
3:05 PM
Halozyme Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
04/29/2024
4:54 PM
Duncan Barbara Gayle (Reporting)
Halozyme Therapeutics (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
04/29/2024
4:56 PM
Halozyme Therapeutics (Issuer)
Henderson Jeffrey William (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
04/29/2024
5:01 PM
Halozyme Therapeutics (Issuer)
Krishnan Mahesh (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
04/29/2024
5:05 PM
Halozyme Therapeutics (Issuer)
MATSUI CONNIE (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
04/29/2024
5:08 PM
Halozyme Therapeutics (Issuer)
Miyashita Akiko Moni (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
04/29/2024
5:11 PM
Halozyme Therapeutics (Issuer)
Posard Matthew L. (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
04/29/2024
4:51 PM
Connaughton Bernadette (Reporting)
Halozyme Therapeutics (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
04/26/2024
3:22 PM
Halozyme Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
04/17/2024
6:22 PM
Halozyme Therapeutics (Issuer)
LaBarre Michael J. (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
03/26/2024
6:38 PM
Halozyme Therapeutics (Issuer)
LaBarre Michael J. (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
03/15/2024
3:46 PM
Halozyme Therapeutics (Filer)
Form ARS
03/15/2024
3:18 PM
Halozyme Therapeutics (Filer)
Form DEFA14A
03/13/2024
4:22 PM
Halozyme Therapeutics (Issuer)
LaBarre Michael J. (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
03/13/2024
3:14 PM
Halozyme Therapeutics (Subject)
LaBarre Michael J. (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
03/04/2024
3:13 PM
Halozyme Therapeutics (Filer)
Form PRE 14A
02/28/2024
5:49 PM
Halozyme Therapeutics (Issuer)
LaBarre Michael J. (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
02/28/2024
3:07 PM
Halozyme Therapeutics (Subject)
LaBarre Michael J. (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
02/20/2024
5:53 PM
Halozyme Therapeutics (Issuer)
LaBrosse Nicole (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
02/20/2024
5:55 PM
Halozyme Therapeutics (Issuer)
Snyder Mark Howard (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
02/20/2024
5:59 PM
Halozyme Therapeutics (Issuer)
LaBarre Michael J. (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
02/20/2024
5:49 PM
Halozyme Therapeutics (Issuer)
Torley Helen (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
02/16/2024
4:39 PM
Halozyme Therapeutics (Issuer)
Torley Helen (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
02/16/2024
4:41 PM
Halozyme Therapeutics (Issuer)
LaBrosse Nicole (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
02/16/2024
4:47 PM
Halozyme Therapeutics (Issuer)
LaBarre Michael J. (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
02/12/2024
5:19 AM
Artisan Partners Limited Partnership (Filed by)
Halozyme Therapeutics (Subject)
Form SC 13G/A
02/01/2024
2:51 PM
Halozyme Therapeutics (Subject)
Invesco Ltd. (Filed by)
Form SC 13G/A
01/17/2024
3:56 PM
Halozyme Therapeutics (Subject)
LaBarre Michael J. (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
01/17/2024
7:10 AM
Halozyme Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
01/16/2024
3:26 PM
Halozyme Therapeutics (Subject)
LaBarre Michael J. (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
12/13/2023
6:48 PM
Halozyme Therapeutics (Issuer)
LaBarre Michael J. (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
12/13/2023
3:40 PM
Halozyme Therapeutics (Subject)
LaBarre Michael J. (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
12/12/2023
3:21 PM
Halozyme Therapeutics (Subject)
LaBarre Michael J. (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
11/14/2023
3:19 PM
Halozyme Therapeutics (Subject)
LaBarre Michael J. (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
11/06/2023
3:04 PM
Halozyme Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
11/06/2023
3:07 PM
Halozyme Therapeutics (Filer)
Form 10-Q
General form for quarterly reports under Section 13 or 15(d)  
10/17/2023
6:28 PM
Halozyme Therapeutics (Issuer)
LaBarre Michael J. (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
09/19/2023
3:30 PM
Halozyme Therapeutics (Subject)
LaBarre Michael J. (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
09/07/2023
6:14 AM
Halozyme Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
08/31/2023
4:35 PM
Halozyme Therapeutics (Issuer)
Torley Helen (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
08/30/2023
3:23 PM
Halozyme Therapeutics (Subject)
Torley Helen (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
Elon’s New Device is About to Shock the World (Ad)

Using this device you see above… Elon Musk just tested a new type of A.I. that according to Wired Magazine will usher in… “The next step in human evolution.”

Click here to see the details because there’s a lot of money at stake.
08/29/2023
4:35 PM
Halozyme Therapeutics (Subject)
Torley Helen (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
08/23/2023
4:08 PM
Halozyme Therapeutics (Issuer)
LaBarre Michael J. (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
08/22/2023
3:20 PM
Halozyme Therapeutics (Subject)
LaBarre Michael J. (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
08/17/2023
5:12 PM
Halozyme Therapeutics (Subject)
Torley Helen (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
08/17/2023
4:29 PM
Halozyme Therapeutics (Issuer)
Torley Helen (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
08/16/2023
4:11 PM
Halozyme Therapeutics (Subject)
Torley Helen (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
08/15/2023
4:02 PM
Halozyme Therapeutics (Subject)
Torley Helen (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
08/14/2023
2:31 PM
Daly James M (Reporting)
Halozyme Therapeutics (Subject)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
08/11/2023
5:44 PM
Daly James M (Reporting)
Halozyme Therapeutics (Subject)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
07/19/2023
3:10 PM
Halozyme Therapeutics (Issuer)
LaBarre Michael J. (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
07/18/2023
3:28 PM
Halozyme Therapeutics (Subject)
LaBarre Michael J. (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
06/22/2023
5:20 PM
Halozyme Therapeutics (Issuer)
LaBarre Michael J. (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
06/21/2023
3:36 PM
Halozyme Therapeutics (Subject)
LaBarre Michael J. (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
06/09/2023
1:15 PM
Halozyme Therapeutics (Subject)
VANGUARD GROUP INC (Filed by)
Form SC 13G/A
(Data available from 1/1/2016 forward)


Related Companies and Tools

This page (NASDAQ:HALO) was last updated on 5/18/2024 by MarketBeat.com Staff

From Our Partners